CN103608018A - 取代的2,3-二氢咪唑并[1,2-c]喹唑啉的用途 - Google Patents
取代的2,3-二氢咪唑并[1,2-c]喹唑啉的用途 Download PDFInfo
- Publication number
- CN103608018A CN103608018A CN201280027514.5A CN201280027514A CN103608018A CN 103608018 A CN103608018 A CN 103608018A CN 201280027514 A CN201280027514 A CN 201280027514A CN 103608018 A CN103608018 A CN 103608018A
- Authority
- CN
- China
- Prior art keywords
- glyoxalidine
- quinazoline
- methoxyl group
- group
- morpholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(NC1=Nc(c(O*)c(cc2)O*)c2C2=NCCN12)=O Chemical compound *C(NC1=Nc(c(O*)c(cc2)O*)c2C2=NCCN12)=O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11161142 | 2011-04-05 | ||
EP11161142.2 | 2011-04-05 | ||
PCT/EP2012/055595 WO2012136549A1 (en) | 2011-04-05 | 2012-03-29 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103608018A true CN103608018A (zh) | 2014-02-26 |
CN103608018B CN103608018B (zh) | 2017-06-30 |
Family
ID=45894478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280027514.5A Expired - Fee Related CN103608018B (zh) | 2011-04-05 | 2012-03-29 | 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的用途 |
Country Status (28)
Country | Link |
---|---|
US (1) | US10202385B2 (und) |
EP (1) | EP2694069A1 (und) |
JP (1) | JP6013446B2 (und) |
KR (1) | KR102006033B1 (und) |
CN (1) | CN103608018B (und) |
AP (1) | AP3751A (und) |
AR (1) | AR088730A1 (und) |
AU (2) | AU2012238887A1 (und) |
BR (1) | BR112013025517A2 (und) |
CA (1) | CA2832120C (und) |
CL (1) | CL2013002869A1 (und) |
CU (1) | CU24349B1 (und) |
DO (1) | DOP2013000224A (und) |
EA (1) | EA027670B1 (und) |
EC (1) | ECSP13013007A (und) |
GT (1) | GT201300235A (und) |
IL (1) | IL228435A0 (und) |
JO (1) | JO3733B1 (und) |
MA (1) | MA35015B1 (und) |
MX (1) | MX2013011582A (und) |
MY (1) | MY169532A (und) |
PE (1) | PE20140571A1 (und) |
SG (1) | SG193577A1 (und) |
TN (1) | TN2013000402A1 (und) |
TW (1) | TWI639599B (und) |
UA (1) | UA114177C2 (und) |
UY (1) | UY33984A (und) |
WO (1) | WO2012136549A1 (und) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101965336B (zh) | 2008-01-04 | 2015-06-17 | 英特利凯恩有限责任公司 | 某些化学实体、组合物和方法 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
EA037577B1 (ru) | 2013-04-08 | 2021-04-16 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ) |
WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
US20150320755A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
KR101665234B1 (ko) * | 2015-02-10 | 2016-10-12 | 순천향대학교 산학협력단 | 골손실의 완화, 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
KR20180013851A (ko) | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 |
US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US10925880B2 (en) | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
US20210187134A1 (en) * | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1400959A (en) | 1919-04-26 | 1921-12-20 | Ste Chim Usines Rhone | Process and apparatus for carrying out chemical reactions by catalysis |
US1539891A (en) | 1920-08-09 | 1925-06-02 | Harry A Lewis | Magnetic lifting device |
US1450048A (en) | 1921-09-24 | 1923-03-27 | Mary S Patterson | Nut lock |
BE397809A (und) | 1932-08-25 | |||
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
WO2002069896A2 (en) * | 2001-03-01 | 2002-09-12 | Northwest Hospital | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
JP2005532070A (ja) * | 2002-07-03 | 2005-10-27 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Mda−7媒介型アポトーシスの調節因子の同定方法 |
ES2367141T3 (es) | 2002-09-30 | 2011-10-28 | Bayer Pharma Aktiengesellschaft | Derivados de azol-pirimidina condensados. |
RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
JP5190233B2 (ja) | 2006-09-01 | 2013-04-24 | パナソニック株式会社 | 無線通信装置 |
US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
EP2244721A4 (en) * | 2008-01-14 | 2017-01-18 | Bayer Intellectual Property GmbH | Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
WO2009126172A1 (en) * | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University In The City Of New York | Resistance to polyphenon e due to increased bcl-2 expression |
CA2721665C (en) | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
US8071315B2 (en) * | 2008-04-30 | 2011-12-06 | Sanford-Burnham Medical Research Institute | Detecting Bcl-B expression in cancer and uses thereof |
FR2932483A1 (fr) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
US8128386B2 (en) | 2008-06-26 | 2012-03-06 | Hamilton Sundstrand Corporation | Variable flow pumping system |
EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
JP5336306B2 (ja) | 2008-10-20 | 2013-11-06 | 信越化学工業株式会社 | レジスト下層膜形成方法、これを用いたパターン形成方法、及びレジスト下層膜材料 |
MX336019B (es) | 2009-05-14 | 2016-01-06 | Bayer Ip Gmbh | Respuesta inmunitaria reforzada en especies aviares. |
CN102958540B (zh) * | 2010-04-16 | 2015-09-02 | 拜耳知识产权有限责任公司 | 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合 |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
UY33821A (es) | 2010-12-22 | 2012-07-31 | Bayer Animal Health Gmbh | Respuesta inmune potenciada en la especie bovina |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
DE112012006927B4 (de) | 2012-09-21 | 2024-01-25 | Toyota Jidosha Kabushiki Kaisha | Hybridfahrzeug-Antriebsvorrichtung |
-
2012
- 2012-03-27 JO JOP/2012/0065A patent/JO3733B1/ar active
- 2012-03-28 TW TW101110917A patent/TWI639599B/zh not_active IP Right Cessation
- 2012-03-28 UY UY0001033984A patent/UY33984A/es not_active Application Discontinuation
- 2012-03-28 AR ARP120101035A patent/AR088730A1/es active Pending
- 2012-03-29 JP JP2014503077A patent/JP6013446B2/ja not_active Expired - Fee Related
- 2012-03-29 SG SG2013071121A patent/SG193577A1/en unknown
- 2012-03-29 MY MYPI2013701876A patent/MY169532A/en unknown
- 2012-03-29 BR BR112013025517A patent/BR112013025517A2/pt not_active Application Discontinuation
- 2012-03-29 CU CUP2013000134A patent/CU24349B1/xx unknown
- 2012-03-29 US US14/009,751 patent/US10202385B2/en active Active
- 2012-03-29 CN CN201280027514.5A patent/CN103608018B/zh not_active Expired - Fee Related
- 2012-03-29 EP EP12710955.1A patent/EP2694069A1/en not_active Withdrawn
- 2012-03-29 CA CA2832120A patent/CA2832120C/en active Active
- 2012-03-29 UA UAA201312764A patent/UA114177C2/uk unknown
- 2012-03-29 AP AP2013007147A patent/AP3751A/en active
- 2012-03-29 MA MA36289A patent/MA35015B1/fr unknown
- 2012-03-29 EA EA201301106A patent/EA027670B1/ru not_active IP Right Cessation
- 2012-03-29 MX MX2013011582A patent/MX2013011582A/es unknown
- 2012-03-29 WO PCT/EP2012/055595 patent/WO2012136549A1/en active Application Filing
- 2012-03-29 KR KR1020137028953A patent/KR102006033B1/ko active IP Right Grant
- 2012-03-29 AU AU2012238887A patent/AU2012238887A1/en not_active Abandoned
- 2012-03-29 PE PE2013002187A patent/PE20140571A1/es not_active Application Discontinuation
-
2013
- 2013-09-15 IL IL228435A patent/IL228435A0/en unknown
- 2013-10-03 TN TNP2013000402A patent/TN2013000402A1/fr unknown
- 2013-10-04 CL CL2013002869A patent/CL2013002869A1/es unknown
- 2013-10-04 GT GT201300235A patent/GT201300235A/es unknown
- 2013-10-04 DO DO2013000224A patent/DOP2013000224A/es unknown
- 2013-11-04 EC ECSP13013007 patent/ECSP13013007A/es unknown
-
2017
- 2017-05-24 AU AU2017203474A patent/AU2017203474B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
Non-Patent Citations (1)
Title |
---|
TORBETT NEIL E ET AL: "A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition", 《BIOCHEM. J.》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10226469B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas | |
AU2017203474B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
US20180042929A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
CN103370320A (zh) | 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉 | |
CN103339133A (zh) | 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉 | |
EP2168582A1 (en) | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
NZ615502B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
NZ712033B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194995 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1194995 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170630 |